Harvard Wyss Institute’s eRapid multiplexed biosensor technology licensed to StataDX to enable new diagnostics for neurological, cardiovascular, and renal diseases
The startup will develop and commercialize cost-effective, highly sensitive, and specific point-of-care diagnostics, applying a novel electrochemical sensor platform created at the Wyss Institute